BioNTech’s first-quarter 2022 sales and earnings more than tripled due to demand for the COVID-19 vaccine the company developed with Pfizer, but the German biotech firm is still forecasting a full-year decline in vaccine sales.
AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Sanofi reported a series of first-quarter 2022 wins, driven mostly by the success of consumer healthcare (CHC) and the company’s blockbuster Dupixent.
Merck makes waves in Q1 2022 with COVID-19 treatment, cancer portfolio
Breakthrough Therapy Designation, Business, COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Earnings per share (EPS), Financials, Forecasts, Keytruda, Market Share, Merck, Pneumococcal Conjugate Vaccines, Pneumococcal Vaccines, Sales, TherapeuticsMerck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.
Eli Lilly’s lucrative Q1 2022 driven by Trulicity and COVID-19 antibodies
Alzheimer’s disease, Bamlanivimab (LY-CoV555), Bebtelovimab (LY-CoV1404; LY3853113), Business, COVID-19 Antibodies, Diabetes, Diabetes drugs, Earnings per share (EPS), Eli Lilly, Etesevimab (Lilly), Financials, Forecasts, Obesity, Obesity, Sales, Therapeutics, TrulicityEli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies.
GSK’s strong Q1 driven by COVID-19, returning demand for shingles vaccine
Antibodies, Business, Business Intelligence, Consumer Health Care, Consumer Healthcare, Coronavirus Disease 2019 (COVID-19), Earnings per share (EPS), Financials, GlaxoSmithKline, Guidance, Leadership, Operations, Presentations, Quarterly results, Sales, Sales, Sales & Marketing, Sales Guidance, Shingles, Strikes, Therapeutics, VaccinesGlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.
Roche sees slowdown in COVID-driven sales growth
Business, Business Intelligence, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Covid-19 antigen tests, COVID-19 Test Kits, COVID-19 Testing, Diagnostics, Earnings per share (EPS), Financials, Forecasts, Portable PCR COVID-19 Test Kits, Roche, Test Kits, TherapeuticsRoche’s first-quarter 2022 sales rose 10 percent on strong U.S. demand for rapid COVID-19 antigen tests and specialty drugs but the Swiss drugmaker reaffirmed that a drop in pandemic-related demand would put the brakes on growth.
Johnson & Johnson rescinded the company’s forecast for sales of its COVID-19 vaccine, as hesitancy in low income countries has led to a glut of supply of a shot once hoped to be the inoculation of choice for the developing world.
Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.
Sanofi Reports Strong Second-Quarter 2019
Acquisitions, Analysts, Asthma, Atopic Dermatitis (Eczema), Business, China, Chronic Rhinosinusitis, Diabetes, Earnings per share (EPS), European Medicines Agency, FDA, Future Blockbusters, Hemophilia, Insulin, Product Launches, Profitability, Quarterly results, R&D, Relapse/Refractory Multiple Myeloma, VaccinesSanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.